ImpediMed Stock

ImpediMed EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of ImpediMed (IPD.AX) as of Aug 6, 2026 is -1.63. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was -0.46 — a change of 258.02% (lower).

EV/OCF

-1.63

YoY

258.02%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of ImpediMed is 2026 -1.63 . EV/OCF (Enterprise Value to Operating Cash Flow) of ImpediMed was 2025 -0.46 . It decreases by 258.02% lower compared to the previous year.
Access this data via the Eulerpool API

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

EV/OCF (Enterprise Value to Operating Cash Flow) of ImpediMed is -1.63 in 2026.

EV/OCF (Enterprise Value to Operating Cash Flow) of ImpediMed changed from -0.46 to -1.63, representing a 258.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) ImpediMed since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s ImpediMed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — ImpediMed

All Key Metrics — ImpediMed